Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;118:S263-S269
doi: 10.1161/CIRCULATIONAHA.107.756502
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hung, J.
Right arrow Articles by Levine, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hung, J.
Right arrow Articles by Levine, R. A.
Related Collections
Right arrow CV surgery: valvular disease
Right arrow Chronic ischemic heart disease

(Circulation. 2008;118:S263-S269.)
© 2008 American Heart Association, Inc.


Surgery for Valvular Heart Disease

A Novel Approach for Reducing Ischemic Mitral Regurgitation by Injection of a Polymer to Reverse Remodel and Reposition Displaced Papillary Muscles

Judy Hung, MD; Jorge Solis, MD; J. Luis Guerrero, BS; Gavin J.C. Braithwaite, PhD; Orhun K. Muratoglu, PhD; Miguel Chaput, MD; Leticia Fernandez-Friera, MD; Mark D. Handschumacher, BS; Van J. Wedeen, MD; Stuart Houser, MD; Gus J. Vlahakes, MD; Robert A. Levine, MD

From Massachusetts General Hospital (J.H., J.S., J.L.G., O.K.M., M.C., L.F.-F., M.D.H., V.J.W., S.H., G.J.V., R.A.L.), Boston, Mass; and Cambridge Polymer, Inc (G.J.C.B.), Boston, Mass.

Correspondence to Judy Hung, MD, Massachusetts General Hospital, Cardiac Ultrasound Laboratory, Blake 256, 55 Fruit Street, Boston, MA 02114. E-mail jhung{at}partners.org

Background— Ischemic mitral regurgitation (MR) relates to displacement of the papillary muscles from ischemic ventricular distortion. We tested the hypothesis that repositioning of the papillary muscles can be achieved by injection of polyvinyl-alcohol (PVA) polymer, a biologically inert biomaterial that has been specially formulated to produce an encapsulated, stable, resilient gel once injected into the myocardium. The purpose is to materially support the infarcted myocardium while at the same time repositioning the papillary muscles that become apically tethered in MR.

Methods and Results— Nine sheep underwent ligation of circumflex branches to produce acute ischemic MR. PVA polymer was then injected by echo guidance into the myocardium underlying the infarcted papillary muscle. Hemodynamic data, left ventricular ejection fraction, elastance, tau (relaxation constant), left ventricular stiffness coefficient, and 2-dimensional and 3-dimensional echocardiograms were obtained post-MR and post-PVA injection. One animal died after coronary ligation and 2 did not develop MR. In the remaining 6, moderate MR developed. With PVA injection, the MR decreased significantly from moderate to trace-mild (vena contracta: 5±0.4 mm versus 2±0.7 mm, post-MR versus post-PVA injection; P<0.0001). This was associated with a decrease in infarcted papillary muscle-to-mitral annulus tethering distance (27±4 to 24±4 mm, post-MR versus post-PVA, P<0.001). Importantly, PVA injection was not associated with significant decreases in left ventricular ejection fraction (43±6% versus 37±4%, post-MR versus post-PVA, P=nonsignificant), elastance (3.5±1.4 versus 2.9±1.3; post-MR versus post-PVA injection, P=nonsignificant). Measures of left ventricular diastolic function, tau (100±51 ms to 84±37 ms, post-MR versus post-PVA; P=nonsignificant), and left ventricular stiffness coefficient (0.18±0.12 versus 0.14±0.08, post-MR versus post-PVA; P=nonsignificant) did not increase post-PVA.

Conclusions— PVA polymer injection resulted in acute reverse remodeling of the ventricle with papillary muscle repositioning to decrease MR. This was not associated with an adverse effect on left ventricular systolic and diastolic function. This new approach to alter pathological anatomy after infarction may offer an alternative strategy for relieving ischemic MR by correcting the position of the affected papillary muscle, thus relieving apical tethering.


Key Words: coronary artery disease • left ventricular remodeling • mitral regurgitation




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
T. G. Di Salvo, M. A. Acker, G. W. Dec, and J. G. Byrne
Mitral Valve Surgery in Advanced Heart Failure
J. Am. Coll. Cardiol., January 26, 2010; 55(4): 271 - 282.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Leor, S. Tuvia, V. Guetta, F. Manczur, D. Castel, U. Willenz, O. Petnehazy, N. Landa, M. S. Feinberg, E. Konen, et al.
Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine.
J. Am. Coll. Cardiol., September 8, 2009; 54(11): 1014 - 1023.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J.-H. Kim, O. Kocaturk, C. Ozturk, A. Z. Faranesh, M. Sonmez, S. Sampath, C. E. Saikus, A. H. Kim, V. K. Raman, J. A. Derbyshire, et al.
Mitral cerclage annuloplasty, a novel transcatheter treatment for secondary mitral valve regurgitation: initial results in swine.
J. Am. Coll. Cardiol., August 11, 2009; 54(7): 638 - 651.
[Abstract] [Full Text] [PDF]